Tedizolid phosphate disodium salt

TargetMol
Product Code: TAR-T1747L
Supplier: TargetMol
CodeSizePrice
TAR-T1747L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1747L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1747L-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Tedizolid phosphate is a novel antibacterial prodrug. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. It also has effective activity against Gram-positive pathogens.
CAS:
856867-39-5
Formula:
C17H14FN6Na2O6P
Molecular Weight:
494.287
Purity:
0.98
SMILES:
[Na+].[Na+].Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1CC(COP([O-])([O-])=O)OC1=O

References

1. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241. PubMed PMID: 23403680. 2. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015;59(6):3252-6. doi: 10.1128/AAC.04376-14. Epub 2015 Mar 23. PubMed PMID: 25801564; PubMed Central PMCID: PMC4432129. 3. O'Riordan W, Green S, Mehra P, De Anda C, Fang E, Prokocimer P. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Infect Dis. 2014 Jan;58 Suppl 1:S43-50. doi: 10.1093/cid/cit617. Review. PubMed PMID: 24343832. 4. Gras J. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783. Review. PubMed PMID: 25525633.